RecruitingPhase 4NCT05830500

Study of Anlotinib in Patients With Advanced Medullary Thyroid Carcinoma

A Real World Study of Anlotinib for Patients With Advanced Medullary Thyroid Carcinoma

Sponsor

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Enrollment

360 participants

Start Date

Jun 19, 2023

Study Type

INTERVENTIONAL

Conditions

Medullary Thyroid Cancer

Summary

This is a real world study aiming to observe the efficacy and safety of Anlotinib capsules in patients with advanced medullary thyroid carcinoma, and to summarize the treatment experience in a broad population of patients.

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This trial is testing the effectiveness of anlotinib — a targeted oral drug that cuts off the blood supply to tumors — in people with advanced medullary thyroid cancer (a rare type of thyroid cancer) that cannot be treated with surgery and is progressing. **You may be eligible if...** - You are 18 years or older with an ECOG performance status of 0–2 - You have been confirmed by biopsy to have inoperable locally advanced or metastatic medullary thyroid cancer - Your disease has been progressing in the past 14 months - You have at least one measurable tumor on scans - Your blood counts, liver, and kidney function meet the required thresholds - Your expected survival is more than 3 months - You are using effective contraception if you are of childbearing potential **You may NOT be eligible if...** - You have had another cancer in the past 3 years (with limited exceptions for long-term survivors) - You have active heart disease, uncontrolled high blood pressure, or a recent bleeding event - You have active liver disease, uncontrolled infections, or are immunocompromised - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGAnlotinib Hydrochloride Capsule

Anlotinib hydrochloride is a muti-target tyrosine kinase inhibitor that inhibits both tumor angiogenesis and tumor cell proliferation simultaneously.

Locations(19)

Anhui Provincial Cancer Hospital

Hefei, Anhui, China

Beijing Tongren Hospital Affiliated to Capital Medical University

Beijing, Beijing Municipality, China

Gansu Cancer Hospital

Lanzhou, Gansu, China

Guangxi Zhuang Autonomous Region Cancer Hospital (Affiliated Cancer Hospital of Guangxi Medical University)

Nanning, Guangxi, China

The First Affiliated Hospital of Hebei North University

Shijiazhuang, Hebei, China

Tianjin Cancer Hospital

Tianjin, Hebei, China

Henan Cancer Hospital

Zhengzhou, Henan, China

The First Affiliated Hospital of Zhengzhou University

Zhengzhou, Henan, China

Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology

Wuhan, Hubei, China

Hubei Cancer Hospital

Wuhan, Hubei, China

Hunan Cancer Hospital

Changsha, Hunan, China

Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University

Nanjing, Jiangsu, China

Jiangsu North People's Hospital

Yangzhou, Jiangsu, China

Liaoning Cancer Hospital and Institute

Shenyang, Liaoning, China

The First Affiliated Hospital of Xi'an Jiaotong University

Xi’an, Shanxi, China

Shanxi Provincial Tumor Hospital

Xi’an, Shanxi, China

Tianjin People's Hospital

Tianjin, Tianjin Municipality, China

The First Affiliated Hospital of Kunming Medical University

Kunming, Yunnan, China

Zhejiang Provincial People's Hospital

Hangzhou, Zhejiang, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05830500

Related Trials

Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors

NCT068144962 locations

Treatment of Advanced Endocrine Tumor With Iindividualized mRNA Neoantigen Vaccine (mRNA-0523-L001)

NCT061413691 location